Published: 7 May 2021
Author(s): Maria Cristina Vedovati, Michela Giustozzi, Maurizio Paciaroni
Issue: June 2021
Section: Commentary

Since their introduction in 2010, non-vitamin K oral anticoagulants (NOACs) changed the landscape of stroke prevention in patients with atrial fibrillation (AF). Because of their favorable benefit-harm profile, the fixed dose administration, the no need for laboratory monitoring and dose adjustment, NOAC prescription increased rapidly and overcome the use of vitamin K antagonists (VKAs) [1,2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.